Cargando…

A Case of Hepatitis E Persistence in a Patient With Myelofibrosis Under Ruxolitinib

Hepatitis E virus (HEV) is a mostly enterically transmitted agent of viral, usually acute hepatitis. In recent years, however, it has been proven to establish chronicity in immunosuppressed patients. We report the first case of HEV infection in a patient with myelofibrosis under ruxolitinib, a tyros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribeiro da Cunha, Maria, Marques, Tiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608255/ https://www.ncbi.nlm.nih.gov/pubmed/34820465 http://dx.doi.org/10.14309/crj.0000000000000674

Ejemplares similares

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
por: Ross, David M., et al.
Publicado: (2021)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
por: Abidi, Maheen Z., et al.
Publicado: (2016)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
por: Sandhu, Sunny, et al.
Publicado: (2022)

Cryptococcal infection with ruxolitinib in primary myelofibrosis: A case report and literature review
por: Ciochetto, Zachary, et al.
Publicado: (2022)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms
por: Bjørn, Mads Emil, et al.
Publicado: (2015)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case
por: Sugiura, Hiroyuki, et al.
Publicado: (2020)

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
por: Aylı, Meltem, et al.
Publicado: (2015)

Ruxolitinib Treatment During Myelofibrosis Leads to Cutaneous Mycobacterium marinum Infection: A Case Report
por: Chen, Xiaonan, et al.
Publicado: (2023)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
por: Koshiishi, Megumi, et al.
Publicado: (2017)

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
por: Beauverd, Yan, et al.
Publicado: (2014)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
por: Peng, Yizhou, et al.
Publicado: (2020)

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
por: Accurso, Vincenzo, et al.
Publicado: (2019)

Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis
por: Koschmieder, Steffen, et al.
Publicado: (2020)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
por: Frankel, Arthur E., et al.
Publicado: (2021)

Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)

Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation
por: Sakoda, Teppei, et al.
Publicado: (2017)

Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature
por: Tsukamoto, Yasuhiro, et al.
Publicado: (2017)

Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review
por: Ogai, Asuka, et al.
Publicado: (2021)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
por: Mesa, Ruben A, et al.
Publicado: (2013)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023)

Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis
por: Miyawaki, Hiroshi, et al.
Publicado: (2019)

Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome
por: Jung, Chul Won
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_no8g5npa6gher6g8tg408uk8km